Continuous infusion followed by subcutaneous injection of campath-1H [alemtuzumab] plus rituximab in the treatment of CD52- and CD20-positive refractory or relapsed chronic lymphoid disorders.

Trial Profile

Continuous infusion followed by subcutaneous injection of campath-1H [alemtuzumab] plus rituximab in the treatment of CD52- and CD20-positive refractory or relapsed chronic lymphoid disorders.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

At a glance

  • Drugs Alemtuzumab; Rituximab
  • Indications Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2011 Actual end date (1 Aug 2007) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Oct 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top